SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS- A COST PER RESPONDER ANALYSIS AT 48 WEEKS FROM A CHILEAN PERSPECTIVE

Author(s)

Rojas R1, Barbeau M2, Jugl SM3, MacPherson A4
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Novartis Pharma AG, Basel, Switzerland, 4Dalhousie University, Halifax, NS, Canada

OBJECTIVES:: The cost per responder analysis attempts to quantify the relative value of two comparator drugs by assessing how the two agents compare in terms of cost per treatment outcome. The objective of this analysis was to estimate and compare the long-term cost per responder based on the American College of Rheumatology outcomes (ACR 20/50/70) following 48 weeks of psoriatic arthritis (PsA) treatment with Secukinumab relative to Adalimumab in Chile. METHODS:: The cost per responder for each treatment was estimated by dividing the retail/private cost, in Chilean Pesos (CLP), for the course of treatment with its response rate. The response rates were derived from a previous matching-adjusted indirect comparison (MAIC). A sensitivity analysis was also conducted by using response rates from a MAIC with a variation of the matching characteristics. RESULTS:: The MAIC showed that ACR (20/50/70) response rates were higher for Secukinumab 150mg and 300mg compared to Adalimumab at 48 weeks. ACR 20 response rates were 80%, 74% and 56%, ACR 50 response rates were 57%, 61% and 44%, whereas the ACR 70 response rates were 32%, 43% and 30% for Secukinumab 150mg, Secukinumab 300 mg, and Adalimumab respectively. The costs per ACR20 responder were $13,768, $29,817 and $31,166, the costs per ACR50 responder were $19,186, $35,698 and $40,138, and the costs per ACR70 responder were $33,887, $51,109, and $58,869, for Secukinumab 150mg, Secukinumab 300mg and Adalimumab respectively. The sensitivity analysis confirmed the findings and showed even more favorable results for Secukinumab. CONCLUSIONS:: ACR 20/50/70 response rates were higher for Secukinumab compared to Adalimumab at 48 weeks. The long term cost per responder for all ACR outcomes at 48 weeks were consistently lower for Secukinumab vs. Adalimumab from a Chilean perspective. These findings indicate that it is more efficient to treat PsA patients with Secukinumab vs. Adalimumab in Chile.

Conference/Value in Health Info

2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PMS17

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Musculoskeletal Disorders, Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×